Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Fierce Biotech
Fierce Biotech
17 articles from Fierce Biotech indexed by Voice Herald. Below is what Fierce Biotech covers most and which stories they have contributed to.
Latest from Fierce Biotech
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
Fierce Biotech
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
Fierce Biotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Fierce Biotech
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board
Fierce Biotech
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
Fierce Biotech
Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax
Fierce Biotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
Fierce Biotech
AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
Fierce Biotech
UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
Fierce Biotech
Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO
Fierce Biotech
FDA urges clinical trial sponsors to report the results of their studies
Fierce Biotech
Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data
Fierce Biotech
Regeneron rides into radiopharma via $2.1B biobucks Telix pact
Fierce Biotech
Gilead pays $3.1B for Tubulis to bolster oncology ADC pipeline
Fierce Biotech
Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
Fierce Biotech
AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops
Fierce Biotech